.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Professor Florian Klein

Cologne / DE

University Hospital Cologne

Speaker

26/03/2024
13:33 – 13:36 3 Min. 0 Min.
Talk
Laudatio GfV Award 2024

Further involvements

25/03/2024
Poster
P 193
CMV in transplant recipients – Identifying patients at high risk for complicated-to-treat CMV infections and combined therapy approach
Virus infections and the immunocompromised host
25/03/2024
Poster
P 188
Torque teno virus load is associated with CDC stage and CD4+ cell count in people living with HIV but unrelated to AIDS-defining events and human pegivirus load
Virus infections and the immunocompromised host
25/03/2024
Poster
P 116
Analysis of Fab fragments from neutralizing antibodies for prevention of cell-associated spread of human cytomegalovirus
Antiviral therapy and resistance
25/03/2024
Poster
P 113
Semen enhances transmitted/founder HIV-1 infection and only marginally reduces antiviral activity of broadly neutralizing antibodies
Antiviral therapy and resistance
25/03/2024
Poster
P 445
A spike mutation compatible with SARS-CoV-2 replication in natura confers resistance to fusion peptide-binding antibodies
Respiratory viruses
25/03/2024
16:00 – 16:15 12 Min. 3 Min.
Abstract talk
O 008
Broad and potent NTD and RBD antibodies for SARS-CoV-2 combination therapy
Adaptive immunity
28/03/2024
12:00 – 12:15 12 Min. 3 Min.
Abstract talk
O 110
Geno2pheno-bNAbs: Interpretable and accurate prediction of HIV bNAb resistance
Antiviral therapy and resistance